Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The newborn drug development initiative.

George P Giacoia1, Debra L Birenbaum, Hari Cheryl Sachs

  • 1Obstetric and Pediatric Pharmacology Branch, Center for Research for Mothers and Children, National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland. gg65m@nih.gov

Pediatrics
|June 17, 2006
PubMed
Summary

The Best Pharmaceuticals for Children Act (BPCA) aims to improve pediatric drug studies. However, drug development for neonates remains insufficient, necessitating better research and ethical considerations for this vulnerable population.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antipsychotic Drugs and the Risk of Diabetic Complications: A Systematic Review of Observational Studies.

Journal of clinical medicine·2026
Same author

Antipsychotic Drugs and the Risk of Diabetic Complications: A Systematic Review of Clinical Evidence.

Journal of clinical medicine·2026
Same author

A matrix for bridging the epidemiology and risk assessment gap.

Global epidemiology·2026
Same author

Trends in Antipsychotic Drug Use in the United States, 2000-2016.

Pharmacy (Basel, Switzerland)·2026
Same author

Safety surveillance of respiratory syncytial virus (RSV) vaccine among pregnant individuals: a real-world pharmacovigilance study using the Vaccine Adverse Event Reporting System.

BMJ open·2025
Same author

Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson's Disease.

Brain sciences·2024

Area of Science:

  • Pediatric Pharmacology
  • Neonatal Drug Development
  • Regulatory Science

Background:

  • The Best Pharmaceuticals for Children Act (BPCA) was enacted in 2002 to facilitate pediatric drug studies.
  • Despite the BPCA, drug development for neonates, the most vulnerable pediatric group, is significantly lacking.
  • Current practices often involve empirical drug administration in neonates based on adult and older pediatric data, compromising safety and efficacy assessments.

Framework:

  • The BPCA established processes for studying both on-patent and off-patent drugs in pediatric populations.
  • The Newborn Drug Development Initiative Workshop I convened to address scientific, clinical, and ethical challenges in neonatal drug trials.
  • The act aims to foster collaboration among federal agencies and academic institutions.

Implementation:

Related Experiment Videos

  • The BPCA's implementation aims to improve the study of drugs used in neonates.
  • Focus on developing appropriate studies to demonstrate short- and long-term safety and efficacy.
  • Establishing appropriate dosing regimens for neonatal patients.

Implications:

  • Enhanced BPCA implementation can foster inter-agency and academic collaboration.
  • Improved scientific investigation and clinical study design for pediatric therapeutics.
  • Addressing ethical considerations crucial for neonatal drug research and development.